Tivic Health Systems, Inc. Announces Pricing of Public Offering

Rhea-AI Summary

Tivic Health Systems, Inc. (Nasdaq: TIVC), a bioelectronic medicine company, announced a public offering of 20 million shares at $0.25 each, aiming for approximately $5 million in gross proceeds. The offering includes a 45-day option for underwriters to purchase an additional 3 million shares. Proceeds will be used for expanding sales of its product ClearUP® for sinus relief and for clinical and regulatory costs related to new product candidates. The offering is expected to close on February 13, 2023, subject to standard conditions.

Positive

• Proceeds will support sales expansion of ClearUP® for sinus relief.
• Funding will cover clinical and regulatory costs for new product candidates.

Negative

• Issuance of shares could lead to shareholder dilution.

SAN FRANCISCO--(BUSINESS WIRE)-- Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced the pricing of an underwritten public offering of an aggregate of 20,000,000 shares of common stock. Each share is being sold to the public at a price of $0.25 per share, for aggregate gross proceeds of approximately $5,000,000, before deducting underwriting discounts and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 3,000,000 shares of common stock to cover over-allotments at the public offering price, less the underwriting discount.

The Company intends to use the proceeds for the continued sales expansion of its first commercial product, ClearUP®, for sinus relief (including the penetration of healthcare professional networks), and clinical and regulatory costs for the expansion of existing and new product candidates. Although the Company, from time to time, evaluates potential strategic investments and acquisitions, it does not have any definitive agreements in place to make any such acquisitions at this current time.

The offering is expected to close on February 13, 2023, subject to satisfaction of customary closing conditions.

ThinkEquity is acting as sole book-running manager for the offering.

A registration statement on Form S-1 (File No. 333-268010) relating to the shares was filed with the Securities and Exchange Commission (“SEC”) and became effective on February 8, 2023. This offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004, by telephone at (877) 436-3673, by email at prospectus@think-equity.com. The final prospectus will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Tivic

Tivic Health Systems, Inc. is a commercial-phase health technology company delivering non-invasive bioelectronic treatments that provide consumers with a choice in the treatment of inflammation and certain other related conditions. For more information visit https://tivichealth.com @TivicHealth.

Forward Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the expected closing date of the offering and intended use of proceeds. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, such as the ability to consummate the offering and satisfy applicable closing conditions. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the public offering filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required under applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230208006051/en/

Media Contact:

Cheryl Delgreco

Cheryl.Delgreco@tivichealth.com

617-429-6749

Kayleigh Westerfield

Kayleigh.Westerfield@tivichealth.com

949-632-3439

Investor Contact:

Hanover International, Inc.

ir@tivichealth.com

Source: Tivic Health Systems, Inc.

FAQ

What is the share price for the TIVC public offering?

The share price for the public offering is $0.25 per share.

How much money is Tivic Health aiming to raise?

Tivic Health aims to raise approximately $5 million in gross proceeds from the offering.

What will the proceeds from the TIVC offering be used for?

Proceeds will be used for expanding sales of ClearUP® and for clinical and regulatory costs for new products.

When is the expected closing date for the TIVC offering?

The expected closing date for the offering is February 13, 2023.

Who is managing the TIVC public offering?

ThinkEquity is acting as the sole book-running manager for the offering.